Vickers SM - Search Results

1

Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?

Irfan A, Fang HA, Awad S, Alkashah A, Vickers SM, Gbolahan O, Williams GR, Nien-Tsu Wang T, Dudeja V, Rose JB, Reddy S. Irfan A, et al. Among authors: vickers sm. Am J Surg. 2022 Sep;224(3):955-958. doi: 10.1016/j.amjsurg.2022.04.004. Epub 2022 Apr 12. Am J Surg. 2022. PMID: 35430088

2

Economics of pancreatoduodenectomy in the elderly.

Vickers SM, Kerby JD, Smoot TM, Shumate CR, Halpern NB, Aldrete JS, Gleysteen JJ. Vickers SM, et al. Surgery. 1996 Oct;120(4):620-5; discussion 625-6. doi: 10.1016/s0039-6060(96)80008-0. Surgery. 1996. PMID: 8862369

3

Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer.

Vickers SM, MacMillan-Crow LA, Green M, Ellis C, Thompson JA. Vickers SM, et al. Arch Surg. 1999 Mar;134(3):245-51. doi: 10.1001/archsurg.134.3.245. Arch Surg. 1999. PMID: 10088562

4

Results of long-term follow-up for transanal excision for rectal cancer.

Gonzalez QH, Heslin MJ, Shore G, Vickers SM, Urist MM, Bland KI. Gonzalez QH, et al. Among authors: vickers sm. Am Surg. 2003 Aug;69(8):675-8; discussion 678. Am Surg. 2003. PMID: 12953825

5

Current status of gene therapy for pancreatic cancer.

Ramírez PJ, Vickers SM. Ramírez PJ, et al. Among authors: vickers sm. Curr Surg. 2004 Jan-Feb;61(1):84-92. doi: 10.1016/j.cursur.2003.07.023. Curr Surg. 2004. PMID: 14972178 Review.

6

Adenoviral gene therapy for pancreatic adenocarcinoma.

Ramírez PJ, Vickers SM. Ramírez PJ, et al. Among authors: vickers sm. Curr Surg. 2004 Jul-Aug;61(4):351-8. doi: 10.1016/j.cursur.2003.10.002. Curr Surg. 2004. PMID: 15276339 Review. No abstract available.

7

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM. Arnoletti JP, et al. Among authors: vickers sm. J Gastrointest Surg. 2004 Dec;8(8):960-9; discussion 969-70. doi: 10.1016/j.gassur.2004.09.021. J Gastrointest Surg. 2004. PMID: 15585383

8

Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.

Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC. Eltoum IA, et al. Am J Clin Pathol. 2005 Nov;124(5):697-707. doi: 10.1309/044P-L9GT-0C3D-B4N4. Am J Clin Pathol. 2005. PMID: 16203289

9

Prognostic factors for survival in pancreatic cancer: a population-based study.

Eloubeidi MA, Desmond RA, Wilcox CM, Wilson RJ, Manchikalapati P, Fouad MM, Eltoum I, Vickers SM. Eloubeidi MA, et al. Among authors: vickers sm. Am J Surg. 2006 Sep;192(3):322-9. doi: 10.1016/j.amjsurg.2006.02.017. Am J Surg. 2006. PMID: 16920426

10

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM. DeRosier LC, et al. Among authors: vickers sm. J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300. doi: 10.1016/j.gassur.2006.08.007. J Gastrointest Surg. 2006. PMID: 17114015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page